Praxis Precision Medicine

Praxis Precision Medicines is the clinical-stage biotech that almost nobody owned at $35 in May 2025 and that is now trading above $340 — a ~10x in 12 months driven by clean Phase 3 readouts on the lead asset and a pipeline that suddenly looks like three shots on goal rather than one.

The headline drug is ulixacaltamide, a selective T-type calcium channel blocker filed with the FDA for adult essential tremor. The EM-1 and EM-2 Phase 3 trials read out positive in 2025: statistically significant reduction in upper-limb tremor versus placebo, with a tolerability profile far cleaner than propranolol or primidon (the current standard of care, both of which have efficacy in only ~50% of patients and significant CNS side-effect baggage). PDUFA decision is expected in mid-2026 — first-line essential tremor is a market of 7-10 million US patients that has had no new approved oral therapy in over thirty years.

Behind ulixacaltamide sits an unusually deep epilepsy pipeline. Relutrigine is a selective NaV1.2/NaV1.6 inhibitor with NDA submission for SCN2A- and SCN8A-developmental and epileptic encephalopathies (ultra-rare pediatric DEEs, orphan pricing power) plus an ongoing Phase 3 in broader DEEs. Vormatrigine is the same mechanism advanced into a Phase 3 program for focal epilepsy — a 1.2 million US-patient market where Vimpat sold >$2B at peak. The Solidus antisense oligonucleotide platform is the optionality layer for 2027 and beyond.

Translation: Praxis went from a single-asset story to a three-NDA-in-eighteen-months story, and the share price reflects the rerating but probably not yet the full peak-sales optionality.

Institutional ownership swung dramatically in 2025. Per Q1/2026 13F filings: RA Capital Management remains the anchor with 7.4% (the firm has been in since the IPO and added through the 2024 lows around $35); Perceptive Advisors increased to 5.2% (new position Q3/2025); Baker Brothers Advisors initiated a 3.1% stake in Q4/2025 — a classic Baker move to come in after Phase 3 readouts when the asymmetry has compressed but the approval optionality is still mispriced.

Insider activity is mixed but informative: CEO Marcio Souza sold $4.8M between July and November 2025 (10b5-1 plan executions at $180-260) but bought back $1.2M in the open market in March 2026 at $290-310 — a meaningful unwind of his own selling at higher prices. CFO Tim Kelly and CMO Bernard Ravina have been net buyers throughout 2026.

Short interest has been the more controversial signal. Days-to-cover sits at 9.3, short-percent-of-float at 13.58% — both are high for a biotech that just delivered clean Phase 3 readouts. The shorts are betting on either (a) FDA delay or label restriction on ulixacaltamide, or (b) a capital raise at a discount before the PDUFA date. The setup is genuinely two-sided.

Praxis is unprofitable by design — the trailing EPS of -$13.38 and forward P/E of -34.97 are not meaningful. Relevant valuation frames are EV/peak-sales-2030 and risk-adjusted NPV. At consensus peak-sales assumptions (ulixacaltamide $2.0B, relutrigine $0.6B orphan, vormatrigine $1.2B), EV/peak-sales sits at 4.2x — versus a mid-cap CNS-biotech peer median of 3.1x. The premium reflects the three-shots-on-goal structure plus the late-stage status of all three.

Sell-side dispersion is extreme: $105 low (assumes ulixacaltamide approval but commercial under-performance), $1,200 high (assumes all three programs approved with peak-sales upside), $651 mean. The implied probability of full pipeline success embedded in the current $342 price is approximately 28% — historical FDA approval rates for de-risked Phase 3 NaV/CaV programs are 70-80% individually. That gap is the asymmetry.

Net cash and short-term investments at last reporting was approximately $370M — enough to fund operations into Q2/2027 but not enough to fund a commercial launch infrastructure for ulixacaltamide without a raise.

1. Mid-2026: Ulixacaltamide PDUFA decision for adult essential tremor — primary stock-moving event
2. H2 2026: Relutrigine NDA acceptance and PDUFA-date assignment for SCN2A/SCN8A-DEE indications
3. Q4 2026 / Q1 2027: Vormatrigine Phase 3 focal-epilepsy interim readout — first major data point on the broader epilepsy franchise

Praxis is the classic biotech you-could-have-bought-at-$35 case study with the twist that, even at $342, the implied probability of the full pipeline working is below 30%. That is the asymmetry: a clean ulixacaltamide approval probably gets you to $450-500 mechanically, and the second NDA on relutrigine is the option layer that nobody is paying for yet.

The risk is genuine and twofold: a 2026 equity raise is virtually certain, and the short interest at 13.58% is not just retail noise — there is institutional bear logic around label restriction. My personal sizing approach for this kind of setup is 1-2% of equity with a hard mental stop at $230 (the 200-day moving average), and aggressive add-on capacity reserved for the PDUFA-decision week. I would not own this as a buy-and-forget — it is a binary trade for the next eight months and then a commercial-execution story after that. If you do not want to hold through a $176M annual burn rate and a likely capital raise, this stock is not for you.